Latest News and Press Releases

Company has formed a new Division, led by Dr. Cyril Empig, to develop a multi-modal approach to treating the COVID-19 and future emergent zoonotic outbreaks Rapid response platform based on the...

AGOURA HILLS, Calif., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD. PhD,...

AGOURA HILLS, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN), dedicated to the development of innovative treatments for cancer, today announced that the...

TrustPoint has the potential to improve documentation processes by automating data documentation and verification leading to improved data integrity and reduced operating expenses Collaboration...

Brings over 20 years of experience in drug development and pharmaceutical manufacturing, as well as Nasdaq listed public company experience EdgePoint AI is to commercialize TrustPoint AI artificial...

AGOURA HILLS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN, “Mateon”) dedicated to the development of...

AGOURA HILLS, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative...

SANTA CLARA, Calif. and AGOURA HILLS, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN)  (‘Mateon”) announced today that they have completed their acquisition of...

AGOURA HILLS, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative...

For treatment of diffuse intrinsic pontine glioma (DIPG), a difficult to treat form of childhood brain tumor AGOURA HILLS, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc....